IBI360
/ Innovent Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 17, 2024
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Completed | Phase classification: P1a/1b ➔ P1 | N=48 ➔ 12
Combination therapy • Enrollment change • Metastases • Monotherapy • Phase classification • Trial completion • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • HER-2
December 17, 2021
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1a/1b; N=48; Recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Combination therapy • Enrollment open • Monotherapy • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • HER-2
September 14, 2021
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1a/1b; N=48; Not yet recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Clinical • Combination therapy • Monotherapy • New P1 trial • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18 • HER-2
1 to 3
Of
3
Go to page
1